Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting SARS-CoV-2 papain-like protease in the postvaccine era
Anh‐Tien Ton, Mohit Pandey, Jason R. Smith, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 11, pp. 906-919
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
İlker Polatoğlu, Tülay Öncü Öner, Irem Dalman, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 43
Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro
Hossein Mousavi, Behzad Zeynizadeh, Mehdi Rimaz
Bioorganic Chemistry (2023) Vol. 135, pp. 106390-106390
Open Access | Times Cited: 24
Cellular targets and lysine selectivity of the HERC5 ISG15 ligase
Xu Zhao, Jessica M. Perez, Peter Faull, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108820-108820
Open Access | Times Cited: 7
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
Fatema Hersi, Anusha Sebastian, Hamadeh Tarazi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115380-115380
Open Access | Times Cited: 16
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Discovery of Pyrano[2,3-c]pyrazole Derivatives as Novel Potential Human Coronavirus Inhibitors: Design, Synthesis, In Silico, In Vitro, and ADME Studies
Abdou K. Allayeh, Aliaa H. El-boghdady, Mohamed A. Said, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 198-198
Open Access | Times Cited: 5
Applications of Machine Learning Approaches for the Discovery of SARS-CoV-2 PLpro Inhibitors
Sourav Pal, Kellie D. Nance, Dirgha Raj Joshi, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential
Mohammed Salah Ayoup, Mariam M. ElShafey, Hamida Abdel‐Hamid, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115272-115272
Open Access | Times Cited: 12
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape
Xinyu Wu, Margareta Go, Julie V. Nguyen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 4
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
Ana C. Puhl, André S. Godoy, G.D. Noske, et al.
ACS Omega (2023) Vol. 8, Iss. 25, pp. 22603-22612
Open Access | Times Cited: 11
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery
Xin Li, Yongcheng Song
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103832-103832
Open Access | Times Cited: 11
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets
Tao Yang, Si Chun Wang, Linyan Ye, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 247-268
Closed Access | Times Cited: 8
Thiophene-fused γ-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation
Gayatri Tehlan, Lennart Brewitz, Lewis T. Ibbotson, et al.
Chemical Science (2024) Vol. 15, Iss. 20, pp. 7667-7678
Open Access | Times Cited: 2
Design, Synthesis, and Biological Evaluation of 1,2,4-Oxadiazole Derivatives Containing an Aryl Carboxylic Acid Moiety as Potent Sarbecovirus Papain-like Protease Inhibitors
Bo Qin, Chengwei Wu, Binbin Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 10211-10232
Closed Access | Times Cited: 2
Molecular Investigations of Novel Pyrano[2,3-c]Pyrazole Congeners as Potential HCoV-229E Inhibitors: synthesis, Molecular Modeling, 3D QSAR, and ADMET Screening
Mohamed G. Abouelenein, Aliaa H. El-boghdady, Hadeer M. Ali, et al.
Polycyclic aromatic compounds (2024), pp. 1-18
Closed Access | Times Cited: 2
Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS‐CoV‐2‐induced CNS complications
Mehdi Valipour
Phytotherapy Research (2023) Vol. 37, Iss. 9, pp. 3724-3743
Closed Access | Times Cited: 6
NMR Characterization of the Papain-like Protease from SARS-CoV-2 Identifies the Conformational Heterogeneity in Its Inhibitor-Binding Site
Yutaro Shiraishi, Ichio Shimada
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16669-16677
Closed Access | Times Cited: 5
Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery
Md. Nazmul Hasan, Manisha Ray, Arjun Saha
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 45, pp. 9663-9684
Closed Access | Times Cited: 5
In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
Calvin R. Wei, Zarrin Basharat, Godwin C. Lang’at
Drugs and Drug Candidates (2024) Vol. 3, Iss. 1, pp. 54-69
Open Access | Times Cited: 1
Antiviral activity of natural compounds extracted from Mediterranean medicinal plants against SARS-CoV-2
Stephanie Ghio, Jean‐Pierre Brincat, Yüksel Çetin, et al.
Academia Biology (2024) Vol. 2, Iss. 3
Open Access | Times Cited: 1
Integrated Computational and Experimental Approaches to Identify New Papain-Like Protease Inhibitors
Rahul Singh, Amit Dhiman, Mahima Chauhan, et al.
Journal of Molecular Structure (2024), pp. 140460-140460
Closed Access | Times Cited: 1
Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
Teena Bajaj, Eddie Wehri, Rahul K. Suryawanshi, et al.
RSC Advances (2023) Vol. 13, Iss. 26, pp. 17667-17677
Open Access | Times Cited: 4
Identification of a novel inhibitor of SARS‐CoV‐2 main protease: an in silico, biochemical, and cell‐based approach
Aditya Trivedi, Vandana Kardam, Krishna Kishore Inampudi, et al.
FEBS Journal (2023) Vol. 290, Iss. 23, pp. 5496-5513
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top